Mostafa Ghanei noted Iran is now domestically producing Factor VIII at the Pharmaceutical Development Center of Tehran University of Medical Sciences which only meets 10 percent of the country’s needs for hemophilia drugs.
“The inauguration of Samen production plan in Mashhad in 6 months will meet all the country’s needs for Factor VIII and cut Iran’s reliance on this product’s import,” he said.
Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). FVIII concentrated from donated blood plasma or alternatively recombinant FVIII can be given to hemophiliacs to restore hemostasis.
The production of FVIII in Iran will help hemophilia treatment be conducted in the country and save up to 50 million dollars as the country cuts reliance on its imports.